Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Blood (2024) 143 (16): 1565–1575.

https://doi.org/10.1182/blood.2023022432

Published: 2024

Journal Articles

Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL): 2-Year Safety and Efficacy Analysis

Michael Wang, Tadeusz Robak, Kami J. Maddocks, Tycel Phillips, Stephen D. Smith, David Gallinson, Roser Calvo, Chuan-Chuan Wun, Veerendra Munugalavadla, Wojciech Jurczak

Blood (2022) 140 (Supplement 1): 6477–6479.

https://doi.org/10.1182/blood-2022-157595

Published: 2022

Journal Articles

Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)

Tycel Phillips, Pieternella Lugtenburg, Anupama Kalsekar, Alex Mutebi, Anthony Wang, Julie Blaedel, Katherine Kosa, Susan Martin, Mariana Sacchi, Catherine Thieblemont

Blood (2022) 140 (Supplement 1): 8022–8023.

https://doi.org/10.1182/blood-2022-159544

Published: 2022

Journal Articles

Mechanistic Insights into Immune Related Toxicities in Subjects with Relapsed/ Refractory Follicular Lymphoma Treated with Zandelisib

Binu Kandathilparambil Sasi, Stephen P. Martindale, Samantha J. Shupe, Stacey M. Fernandes, Saurabh Yadav, John-Hanson Machado, Tycel Phillips, Andrew D. Zelenetz, Jennifer R. Brown

Blood (2022) 140 (Supplement 1): 3575–3576.

https://doi.org/10.1182/blood-2022-159167

Published: 2022

Journal Articles

Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2022) 140 (Supplement 1): 9443–9445.

https://doi.org/10.1182/blood-2022-158245

Published: 2022

Journal Articles

Follicular Lymphoma Treatment Patterns and Outcomes over Time: A Real-World Analysis in the United States

Tycel Phillips, Junhua Yu, Rajesh Kamalakar, Kalatu R. Davies, Alex Mutebi, Savreet Bains Chawla, Donald Arnette, Syed Quadri, Anthony Wang

Blood (2022) 140 (Supplement 1): 5241–5243.

https://doi.org/10.1182/blood-2022-157773

Published: 2022

Journal Articles

Subcutaneous Epcoritamab + R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results

Pau Abrisqueta, Raul Cordoba, Lorenzo Falchi, Sven de Vos, Marcel Nijland, Fritz Offner, Jun Wu, Irina Bykhovski, Liwei Wang, Ali Rana, Tycel Phillips

Blood (2022) 140 (Supplement 1): 1068–1069.

https://doi.org/10.1182/blood-2022-158278

Published: 2022

Journal Articles

Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study

Jennifer A. Woyach, Ian W. Flinn, Farrukh T. Awan, Herbert Eradat, Danielle M. Brander, Michael Tees, Sameer A. Parikh, Tycel Phillips, Wayne Wang, Nishitha M. Reddy, Mohammed Z.H. Farooqui, John C. Byrd, Deborah M. Stephens

Blood (2021) 138 (Supplement 1): 392.

https://doi.org/10.1182/blood-2021-148672

Published: 2021

Journal Articles

Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Blood (2021) 138 (Supplement 1): 128.

https://doi.org/10.1182/blood-2021-148778

Published: 2021

Journal Articles

Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy

Tycel Phillips, Michael Dickinson, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Marek Trněný, Nancy L. Bartlett, Jan Zaucha, Kathryn Humphrey, David Perez-Callejo, Linda Lundberg, James Relf, Audrey Filézac de L'Étang, David Carlile, Emma Clark, Carmelo Carlo-Stella

Blood (2021) 138 (Supplement 1): 130.

https://doi.org/10.1182/blood-2021-148949

Published: 2021

Journal Articles

Safety and Efficacy of Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL)

Michael Wang, Tadeusz Robak, Kami J. Maddocks, Tycel Phillips, Stephen D. Smith, David Gallinson, Roser Calvo, Chuan-Chuan Wun, Veerendra Munugalavadla, Wojciech Jurczak

Blood (2021) 138 (Supplement 1): 2416.

https://doi.org/10.1182/blood-2021-146615

Published: 2021

Journal Articles

An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Stem Cell Transplantation for Frontline, Stage III or IV Classical Hodgkin Lymphoma Based on the 5-Year Update of the ECHELON-1 Trial: A United States Perspective

Tycel Phillips, Kristen Migliaccio-Walle, Kristina S. Yu, Brian Bloudek, Nicholas Liu, Michelle A. Fanale, John M. Burke

Blood (2021) 138 (Supplement 1): 2440.

https://doi.org/10.1182/blood-2021-147308

Published: 2021

Journal Articles

Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

Connie Lee Batlevi, Steven I. Park, Loretta Nastoupil, Tycel Phillips, Jennifer E. Amengual, David Andorsky, Philip Campbell, Pamela McKay, John M. Pagel, John P. Leonard, Jay Yang, Heather O'Connor, Anthony Hamlett, Deyaa Adib, Franck Morschhauser

Blood (2021) 138 (Supplement 1): 2207.

https://doi.org/10.1182/blood-2021-148199

Published: 2021

Journal Articles

An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Overall Survival Based on the 5-Year Update from the ECHELON-2 Trial in Frontline Patients with Peripheral T-Cell Lymphoma: A United States Perspective

John M. Burke, Kristina S. Yu, Uche Mordi, Brian Bloudek, Nicholas Liu, Michelle A. Fanale, Tycel Phillips

Blood (2021) 138 (Supplement 1): 2466.

https://doi.org/10.1182/blood-2021-148004

Published: 2021

Journal Articles

TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data

Sarit Assouline, Amitkumar Mehta, Tycel Phillips, Lapo Alinari, Alexey V. Danilov, Stéphane Doucet, Steven I. Park, Deborah Berg, Alejandro Gomez-Pinillos, Alonzo Martinez, Bo Chao, Allison J Berger, John Gibbs, Sharon Friedlander, Christine K. Ward, Igor Proscurshim, Brenda W. Cooper, Paolo F Caimi

Blood (2021) 138 (Supplement 1): 2488.

https://doi.org/10.1182/blood-2021-152225

Published: 2021

Journal Articles

Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma

Krish Patel, Jean-Marie Michot, Asher Chanan-Khan, Herve Ghesquieres, Kamal Bouabdallah, John C. Byrd, Guillaume Cartron, Craig A. Portell, Melhem Solh, Hervé Tilly, William G. Wierda, Patricia McGovern, Chelsea Johnson, Raman Garcha, Vincent Ribrag, Gabriel Brisou, David Liebowitz, Tycel Phillips

Blood (2021) 138 (Supplement 1): 2494.

https://doi.org/10.1182/blood-2021-144350

Published: 2021

Journal Articles

Molecular and Genetic Characterization of Tumor Samples from Patients with Relapsed or Refractory Follicular Lymphoma Identifies Factors Influencing Response to Tazemetostat

Sandeep S. Dave, Lanie Happ, Christopher Yasso, Gilles Salles, Connie Lee Batlevi, Tycel Phillips, Jay Yang, Deyaa Adib, Neil R. Michaud, Franck Morschhauser

Blood (2021) 138 (Supplement 1): 1183.

https://doi.org/10.1182/blood-2021-151452

Published: 2021

Journal Articles

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204)

Tycel Phillips, Abraham Avigdor, Ronit Gurion, Caterina Patti, Paolo Corradini, Monica Tani, Amitkumar Mehta, Izidore S. Lossos, Pier Luigi Luigi Zinzani, Catherine Thieblemont, Wojciech Jurczak, Fred Zheng, Erica Rappold, Wanying Zhao, Peter Johnson

Blood (2021) 138 (Supplement 1): 44.

https://doi.org/10.1182/blood-2021-147778

Published: 2021

Journal Articles

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Andrew M. Evens, Alexey Danilov, Deepa Jagadeesh, Amy Sperling, Seo-Hyun Kim, Ryan Vaca, Catherine Wei, Daniel Rector, Suchitra Sundaram, Nishitha Reddy, Yong Lin, Umar Farooq, Christopher D'Angelo, David A. Bond, Stephanie Berg, Michael C. Churnetski, Amandeep Godara, Nadia Khan, Yun Kyong Choi, Maryam Yazdy, Emma Rabinovich, Gaurav Varma, Reem Karmali, Agrima Mian, Malvi Savani, Madelyn Burkart, Peter Martin, Albert Ren, Ayushi Chauhan, Catherine Diefenbach, Allandria Straker-Edwards, Andreas K. Klein, Kristie A. Blum, Kirsten Marie Boughan, Scott E. Smith, Brad M. Haverkos, Victor M. Orellana-Noia, Vaishalee P. Kenkre, Adam Zayac, Jeremy Ramdial, Seth M. Maliske, Narendranath Epperla, Parameswaran Venugopal, Tatyana A. Feldman, Stephen D. Smith, Andrzej Stadnik, Kevin A. David, Seema Naik, Izidore S. Lossos, Matthew A. Lunning, Paolo Caimi, Manali Kamdar, Neil Palmisiano, Veronika Bachanova, Craig A. Portell, Tycel Phillips, Adam J. Olszewski, Juan Pablo Alderuccio

Blood (2021) 137 (3): 374–386.

https://doi.org/10.1182/blood.2020006926

Published: 2021

Includes: Supplemental data

Journal Articles

Outcomes Following Salvage Therapy in Primary Refractory Peripheral T-Cell Lymphoma (PTCL)

Janie Y Zhang, MD, Robert Briski, BS, Sumana Devata, MD, Mark S Kaminski, MD, Tycel Phillips, MD, Tera Mayer, NP, Nathanael G Bailey, MD, Ryan A Wilcox, MD PhD

Blood (2016) 128 (22): 4152.

https://doi.org/10.1182/blood.V128.22.4152.4152

Published: 2016

NARROW

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL): 2-Year Safety and Efficacy Analysis

Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)

Mechanistic Insights into Immune Related Toxicities in Subjects with Relapsed/ Refractory Follicular Lymphoma Treated with Zandelisib

Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Follicular Lymphoma Treatment Patterns and Outcomes over Time: A Real-World Analysis in the United States

Subcutaneous Epcoritamab + R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results

Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study

Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy

Safety and Efficacy of Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL)

An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Stem Cell Transplantation for Frontline, Stage III or IV Classical Hodgkin Lymphoma Based on the 5-Year Update of the ECHELON-1 Trial: A United States Perspective

Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma

An Oncology Simulation Model to Estimate 10-Year Progression-Free Survival and Overall Survival Based on the 5-Year Update from the ECHELON-2 Trial in Frontline Patients with Peripheral T-Cell Lymphoma: A United States Perspective

TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data

Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma

Molecular and Genetic Characterization of Tumor Samples from Patients with Relapsed or Refractory Follicular Lymphoma Identifies Factors Influencing Response to Tazemetostat

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204)

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Outcomes Following Salvage Therapy in Primary Refractory Peripheral T-Cell Lymphoma (PTCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only